# The Safety ,Tolerability and Efficacy Study of HepaCure in Chinese Subjects with Acute-On-Chronic Liver Failure

> **NCT05989958** · PHASE1,PHASE2 · RECRUITING · sponsor: **Hexaell Biotech Co., Ltd.** · enrollment: 92 (estimated)

## Conditions studied

- Acute on Chronic Hepatic Failure
- Liver Failure
- Hepatitis

## Interventions

- **COMBINATION_PRODUCT:** HepaCure
- **DEVICE:** DPMAS and LPE

## Key facts

- **NCT ID:** NCT05989958
- **Lead sponsor:** Hexaell Biotech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-09-22
- **Primary completion:** 2026-09
- **Final completion:** 2026-09
- **Target enrollment:** 92 (ESTIMATED)
- **Last updated:** 2025-02-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05989958

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05989958, "The Safety ,Tolerability and Efficacy Study of HepaCure in Chinese Subjects with Acute-On-Chronic Liver Failure". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05989958. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*